Vyteris wants to give up drug-delivery ghost

The drug-delivery business isn't for everybody. And New Jersey-based Vyteris wants out, according to an article on in-PharmaTechnologist. Vyteris is hanging a "for sale" sign on its adhesive, patch-based technology platform. The future for Vyteris, the company says, is in acquiring contract research organizations. Vyteris no doubt does see CROs as a good investment, but, as in-PharmaTechnologist points out, there's probably more to the story. "However, while recognition of these trends was undoubtedly a motivation, Vyteris' decision to refocus as a CRO also reflects the difficulties it has had with its delivery technology business," the article says. Read it all here

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.